Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related ...

A former alderman and Davenport mayoral candidate has filed suit against the Davenport City Council, accusing the council of ...

Genesis Energy is a strong sell as high leverage, weak cash flow, and shaky EBITDA add-backs threaten its 4.2% yield. Read ...

The Safe Streets For All project is continuing onward for the city, with the most recent step in the process being a presentation on the project to the city Planning Commission. John Hartley with Stan ...

Shareholder/Analyst Call April 30, 2026 4:00 PM EDTCompany ParticipantsScott Taylor - VP & CFOMartti Aarnio-WihuriM.

Despite receiving $15 million in emergency state funding, SOU must still cut faculty, staff and programs to shore up its ...

A Research Evening offered students the opportunity to share different research findings they conducted for course ...

Leading ophthalmic CRO Ora unveils breakthrough research in ophthalmology clinical trials, new Blind Canvas Project content ...

Live Updates 10 Minutes to Rivian's Conference Call - Here Are the Important Metrics You Need to Know 1 hour ago Live Rivian ...

PanGIA Biotech, Inc. ("PanGIA Biotech" or "Company") announced that two research abstracts have been accepted for presentation at the American Association for Cancer Research ("AACR") Annual Meeting ...

Delivered record first quarter operating revenues of $5.8 billion driven by strong demand across the networkOperating income ...

Presentation reinforces ATH434's clinical profile ahead of Phase 3 engagement with regulators - MELBOURNE, Australia and SAN FRANCISCO, April 22, 2026 (GLOBE NEWSWIRE)-- Alterity Therapeutics (ASX: ...